Unplanned admissions for patients with myeloma in the UK : Low frequency but high costs
Kolovos, Spyros (University of Oxford. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences)
Nador, Guido (Oxford University Hospitals NHS Trust)
Kishore, Bhuvan (Heart of England NHS Foundation Trust)
Streetly, Matthew (King's College London)
Rabin, Neil K. (Department of Haematology, University College London Hospitals NHS Foundation Trust)
Chantry, Andrew D. (Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield, Regne Unit))
Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit))
Ashcroft, John (Department of Haematology, Mid Yorkshire NHS Trust)
Bowcock, Stella (King's College Hospital NHS Foundation Trust)
Drayson, Mark T. (Institute of Immunology and Immunotherapy, University of Birmingham)
Ramasamy, Karthik (Oxford University Hospitals NHS Trust)
Prieto-Alhambra, Daniel (Universitat Autònoma de Barcelona)
Cooper, Cyrus (NIHR Oxford Biomedical Research Centre)
Javaid, M. Kassim (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford)
Pinedo-Villanueva, Rafael (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford)

Date:	2019
Abstract:	Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS). Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018. A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4. 5% with costs increasing 1. 5% per year; for unplanned admissions, these figures were 4. 1% and 9. 0%, respectively. MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Multiple myeloma ; Unplanned admissions ; Elective admissions ; Costs
Published in:	Journal of Bone Oncology, Vol. 17 (august 2019) , ISSN 2212-1374

DOI: 10.1016/j.jbo.2019.100243
PMID: 31223562

8 p, 1.6 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles